The Global Ventricular Tachycardia Market is estimated to be valued at USD 15.52 Bn in 2025 and is expected to reach USD 22.28 Bn by 2032, reflecting a compound annual growth rate (CAGR) of 5.3% from ...

"This represents an important milestone in ensuring that Rapiblyk™ availability is secured nationwide, supporting clinicians ...

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...

(RTTNews) - Milestone Pharmaceuticals Inc. (MIST) is awaiting a pivotal U.S. FDA decision this month on the company's lead drug candidate, CARDAMYST nasal spray, for the acute treatment of paroxysmal ...

UT Health San Antonio Multispecialty and Research Hospital became the first in South Texas to use an emerging and less-invasive treatment called radiofrequency ablation on a comorbid patient with a ...

New research from Intermountain Health in Salt Lake City finds that patients diagnosed with peripheral arterial disease (PAD) who also have atrial fibrillation (AFib) face a significantly higher risk ...

Introduction: Implanted vagus nerve stimulators (VNS) have become an established therapy for treatment-resistant epilepsy and major depressive disorder (MDD), and the scope of its potential ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...